U.S. FDA approves Cepheid’s COVID-19 test to expand frontline testing
Category: #health  By Saipriya Iyer  Date: 2020-03-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

U.S. FDA approves Cepheid’s COVID-19 test to expand frontline testing

The U.S. FDA (Food and Drug Administration) has recently approved Cepheid’s COVID-19 test in response to the public health emergency caused by the coronavirus. The new test can help expand the availability of frontline testing in clinics and hospitals, without the need for round-tripping to a diagnostic lab. The federal agency has been rapidly focusing on granting emergency use authorization to tests and equipment to address the accelerating spread of the virus in the United States.

COVID-19 test of Cepheid has a distinct advantage over other tests, as it functions with or without the use of nasal swabs. This is considered advantageous because the nasal swabs supplies have been taxed globally. The new tests will be shipped out by the company from next week. The test, which is molecular and PCR-based, also has high level of accuracy as that of the lab-based testing in various U.S. facilities. However, it adopts Cepheid’s GeneXpert machine, which is a diagnostic kit, to ensure on-site delivery of results.

Nearly 23,000 GeneXpert micro-labs of the American molecular diagnostic company have reportedly been adopted across the world, with over 5,000 that are based in the U.S. Cepheid’s hardware has been running flu-related tests since many years and has high reliability rates.

The testing capacity in the U.S. has been increased in the past few weeks owing to widespread efforts to enhance its availability and cater to the hard-hit regions such as NYC by coronavirus pandemic. However, the demand for tests is rising continuously and this limited availability has resulted in only severe cases, with proof of elevated risk or confirmed contract tracing, being tested.

In order to effectively inform any coronavirus mitigation strategies, various testing solutions similar to that of Cepheid and other potential and accurate testing alternatives that can be carried out at home, such as the forthcoming antibodies test introduced by Scanwell, etc. are needed to expand the testing capabilities to the highest degree.

Source credit:

https://finance.yahoo.com/news/type-covid-19-test-now-134500434.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Alibaba to acquire 10% stake in Yunda from controlling shareholders
Alibaba to acquire 10% stake in Yunda from controlling shareholders
By Saipriya Iyer

Alibaba Group Holding Limited, a Chinese multinational technology company, is reportedly planning to purchase nearly 10% stakes in Yunda Holding Co Ltd. This acquisition marks the e-Commerce company’s 5th investm...

Amazon warehouse workers plan walkout in NYC due to COVID-19 fear
Amazon warehouse workers plan walkout in NYC due to COVID-19 fear
By Saipriya Iyer

A group of Amazon workers at its New York City facility reportedly held a walk out and went on strike over the lack of safety protocols by the e-Commerce giant, amid COVID-19 pandemic concerns. These workers further de...

Regeneron-Sanofi announce 1st patient for clinical study outside U.S.
Regeneron-Sanofi announce 1st patient for clinical study outside U.S.
By Saipriya Iyer

Regeneron Pharmaceuticals, Inc. & Sanofi have recently announced the 1st patient to be treated in the COVID-19 clinical program, outside of the United States. The study, which is anticipated to enroll nearly 300 pa...